M
Margaret K. Callahan
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 183
Citations - 37096
Margaret K. Callahan is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ipilimumab & Nivolumab. The author has an hindex of 52, co-authored 157 publications receiving 29313 citations. Previous affiliations of Margaret K. Callahan include Bristol-Myers Squibb & University of Connecticut Health Center.
Papers
More filters
Journal ArticleDOI
Responders to anti-PD1 therapy: Long-term outcomes and responses to retreatment in melanoma (mel).
Allison Betof Warner,Jessica S. Palmer,Alexander N. Shoushtari,Debra A. Goldman,Katherine S. Panageas,Margaret K. Callahan,Jedd D. Wolchok,Michael A. Postow,Paul B. Chapman +8 more
TL;DR: This data indicates that continuation of anti-PD1 therapy after a complete response (CR) outside of clinical trials is likely to be aogeneously withdrawn in patients with a history of central giant cell granuloma.
Journal ArticleDOI
Concurrent Radiation Therapy (RT), Ipilimumab (Ipi) and/or Nivolumab (Nivo) on a Phase 1 Clinical Trial
Christopher A. Barker,Michael A. Postow,S.A. Kronenberg,Jennifer Ma,Yoshiya Yamada,K. Beal,Timothy A. Chan,Margaret K. Callahan,Jedd D. Wolchok +8 more
Proceedings ArticleDOI
Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial
Roberta Zappasodi,Yanyun Li,Mohsen Abu-Akeel,Jingjing Qi,Philip C. Wong,Cynthia Sirard,Michael A. Postow,David Schaer,Walter Newman,Henry B. Koon,Vamsidhar Velcheti,Margaret K. Callahan,Jedd D. Wolchok,Taha Merghoub +13 more
TL;DR: Initial in vitro analyses indicate that GITR stimulation with TRX-518 destabilizes Treg phenotype by down-regulating Foxp3 and enhancing expression of the prototype Th1-lineage transcription factor T-bet, thus explaining the effect of Treg loss observed in patients.
Journal ArticleDOI
Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
James W. Smithy,Matthew J. Pianko,Colleen Maher,Michael A. Postow,Alexander N. Shoushtari,Alexander N. Shoushtari,Parisa Momtaz,Paul B. Chapman,Jedd D. Wolchok,Jae H. Park,Margaret K. Callahan,Margaret K. Callahan +11 more
TL;DR: Patients with locally advanced or metastatic melanoma and a concomitant diagnosis of CLL who received pembrolizumab or ipilimumab with or without nivolumab for the treatment of their melanoma were retrospectively identified and showed clinical activity, consistent with those previously reported.
Journal ArticleDOI
Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
Claire F. Friedman,Pedram Navid-Azarbaijani,Alexander N. Shoushtari,Shonnette C. Campbell,Margaret K. Callahan,Parisa Momtaz,Nana A. Prempeh-Keteku,Michael A. Postow,Yelena Shames,Jedd D. Wolchok,Paul B. Chapman +10 more
TL;DR: The clinical experience of toxicity in pts enrolled in the Ipi+Nivo EAP is reported, and Clinically significant immune-related adverse events (irAEs) were defined as CTCAE v4.0 grade ≥ 2 or grade 1 events requiring systemic steroids.